- Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld.
- Ray T.
- Precision Oncology News. 2023 Jan 23.
- Case report
- Free Full Text
- Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
- Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
- Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.
- PMID: 36686677
- PubMed abstract
- Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
- Drogan CM, Kindler HL, Gao G, Kupfer SS.
- JCO Precis Oncol. 2023 Jan;7:e2200196. doi: 10.1200/PO.22.00196.
- PMID: 36689696
- PubMed abstract
- Source abstract